drugset / Trial / NCT02684708
Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
Phase 3
Completed
2921 enrolled
University of Giessen
Deutsche Krebshilfe e.V., Bonn (Germany) · collabEuronet Worldwide · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.
Timeline
- Start
- 2015-10-01
- Primary completion
- 2024-10-31
- Completion
- 2025-10-31
Publications
- Pabari R, McCarten K, Flerlage J, Lai H, Mauz-Korholz C, Dieckmann K, Palese M, Kaste S, Castellino SM, Kelly KM, Stoevesandt D, Kurch L. Hodgkin lymphoma involving the extra-axial CNS: an AHOD1331, PHL-C1, and PHL-C2 report from the COG and EuroNet-PHL. Blood Adv. 2024 Sep 24;8(18):4856-4865. doi: 10.1182/bloodadvances.2023012346.
- Drechsel KCE, Pilon MCF, Stoutjesdijk F, Meivis S, Schoonmade LJ, Wallace WHB, van Dulmen-den Broeder E, Beishuizen A, Kaspers GJL, Broer SL, Veening MA. Reproductive ability in survivors of childhood, adolescent, and young adult Hodgkin lymphoma: a review. Hum Reprod Update. 2023 Jul 5;29(4):486-517. doi: 10.1093/humupd/dmad002.
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Other |
| Comparator | Cyclophosphamide | Other / unclassified | 625 mg/m2 | Other |
| Subject | Doxorubicin | Other / unclassified | 25 mg/m2 | Other |
| Subject | Etoposide | Small molecule | 100 mg/m2 | Other |
| Comparator | Dacarbazine | Small molecule | 250 mg/m2 | Other |
| Comparator | Prednisone | Other / unclassified | 40 mg/m2 | Oral |
| Comparator | Vincristine | Small molecule | 1.5 mg/m2 | Intravenous |